PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Conditions
Recurrent Nasopharyngeal Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Peking University Third Hospital, Beijing, China
Contact: Study coordinator (Suqing Tian)Sichuan Cancer Hospital, Chengdu, China
Contact: Study coordinator (Shun Lu)Fujian Province Cancer Hospital, Fuzhou, China
Contact: Study coordinator (Shaojun Lin)Guizhou Cancer Hospital, Guiyang, China
Contact: Study coordinator (Feng Jin)Zhejiang Cancer Hospital, Hangzhou, China
Contact: Study coordinator (Xiaozhong Chen)Jiangxi Cancer Hospital, Nanchang, China
Contact: Study coordinator (Jingao Li)The First Affiliated Hospital of Guangxi Medical University, Nanning, China
Contact: Study coordinator (Rengshen Wang)Fudan University Shanghai Cancer Center, Shanghai, China
Contact: Study coordinator (Chaosu Hu)Zhongnan Hospital of Wuhan University, Wuhan, China
Contact: Study coordinator (Conghua Xie)Xijing Hospital, Xi'an, China
Contact: Study coordinator (Mei Shi)The First Affiliated Hospital of Xiamen University, Xiamen, China
Contact: Study coordinator (Qin Lin)
Study leads
Chong Zhao
Principal Investigator
Sun Yat-Sen University Cancer Center